Alpha-blockade therapy in alternating day dose in the management of benign prostatic hyperplasia

ABSTRACT

This study was conducted to compare the efficacy of Terazosin given in alternate day doses with that of the same drug given in daily doses in the medical management of benign prostatic hyperplasia (BPH) using the following parameters International Prostate Symptom Score (IPSS), urine flow rate, residual urine volume and quality of life. Ninety patients were randomly assigned to Daily Dose, Alternate Day Dose and Placebo groups. Symptom scores using the IPSS were measured at pre-treatment, and at 1st, 3rd and 6th week treatment periods. Pre- and post-treatment measurements of urine flow rate, residual urine volume and quality of life were done. Two-way ANOVA and Wilcoxon Matched Pair Signed Ranked Test was used to determine the level of significance. The study showed that there was significant improvement in the symptom score in both Daily Dose (15.80 +/- 1.74 to 5.93 +/- 1.03) (p 0.001) and Alternate Day Dose group (16.06 +/- 1.87 to 6.13 +/- 1.45) (p 0.001) compared to the placenta group. Likewise there was significant improvement in the urine flow rate in both groups, (4.82 +/- 0.75 to 5.76 +/- 0.67) (p (65.66 +/- 17.54 to 46.46 +/- 12.77) (p = 0.001) in the Alternate Day Dose group. The quality of life improved (3.26 +/- 0.88 to 1.66 +/- 0.72) (p = 0.002) in the Daily Dose group and (3.66 +/- 0.81 to 1.80 +/- 0.77) (p = 0.001) in the Alternate Day Dose group. (Author)